SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Farnebo Marianne)
 

Search: WFRF:(Farnebo Marianne) > WRAP53 beta, surviv...

WRAP53 beta, survivin and p16(INK4a) expression as potential predictors of radiotherapy/chemoradiotherapy response in T2N0-T3N0 glottic laryngeal cancer

Tiefenböck Hansson, Katharina (author)
Linköpings universitet,Avdelningen för cellbiologi,Medicinska fakulteten,Region Östergötland, Öron- näsa- och halskliniken US
Haapaniemi, Aaro (author)
Helsinki University Hospital, Finland; University of Helsinki, Finland
Farnebo, Lovisa (author)
Linköpings universitet,Avdelningen för Logopedi, Audiologi och Otorhinolaryngologi,Medicinska fakulteten,Region Östergötland, Öron- näsa- och halskliniken US
show more...
Palmgren, Bjorn (author)
Karolinska University Hospital, Sweden
Tarkkanen, Jussi (author)
University of Helsinki, Finland; Helsinki University Hospital, Finland
Farnebo, Marianne (author)
Karolinska Institutet,Karolinska Institute, Sweden
Munck-Wikland, Eva (author)
Karolinska Institutet,Karolinska University Hospital, Sweden
Makitie, Antti (author)
Karolinska Institutet,Helsinki University Hospital, Finland; University of Helsinki, Finland; Karolinska University Hospital, Sweden
Garvin, Stina, 1977- (author)
Linköpings universitet,Avdelning för neurobiologi,Medicinska fakulteten,Region Östergötland, Klinisk patologi
Roberg, Karin (author)
Linköpings universitet,Avdelningen för cellbiologi,Medicinska fakulteten,Region Östergötland, Öron- näsa- och halskliniken US
show less...
 (creator_code:org_t)
2017-08-11
2017
English.
In: Oncology Reports. - : SPANDIDOS PUBL LTD. - 1021-335X .- 1791-2431. ; 38:4, s. 2062-2068
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • The current treatment recommendation for T2-3N0M0 glottic squamous cell carcinoma (SCC) in the Nordic countries comprises of radiotherapy (RT) and chemoradiotherapy (CRT). Tumor radiosensitivity varies and another option is primary surgical treatment, which underlines the need for predictive markers in this patient population. The aim of the present study was to investigate the relation of the proteins WRAP53 beta, survivin and p16INK4a to RT/CRT response and ultimate outcome of patients with T2-T3N0 glottic SCC. Protein expression was determined using immunohistochemistry on tumors from 149 patients consecutively treated with RT or CRT at Helsinki University Hospital, Karolinska University Hospital, and Linkping University Hospital during 1999-2010. Our results demonstrate a significantly better 5-year relapse-free survival, disease-free survival (DFS), disease-specific survival and overall survival of patients with T3N0 tumors treated with CRT compared with RT alone. Patients with tumors showing a cytoplasmic staining of WRAP53 beta revealed significantly worse DFS compared with those with nuclear staining. For survivin, we observed a trend towards better 5-year DFS in patients with strong nuclear survivin expression compared with those with weak nuclear survivin expression (p=0.091). Eleven (7%) tumors showed p16 positivity, with predilection to younger patients, and this age group of patients with p16-positive SCC had a significantly better DFS compared with patients with p16-negative SCC. Taken together, our results highlight WRAP53 beta as a potential biomarker for predicting RT/CRT response in T2-T3N0 glottic SCC. p16 may identify a small but distinct group of glottic SCC with favorable outcome. Furthermore, for T3N0 patients better outcome was observed following CRT compared to RT alone.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)

Keyword

head and neck cancer; radiotherapy; chemoradiotherapy; survival; recurrence; biomarker; WRAP53 beta; survivin; p16

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view